DDInter927 DDInter817
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status.
Gilteritinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Gilteritinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Gilteritinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pentamidine
Gilteritinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Deutetrabenazine
Gilteritinib {u} may lead to a major life threatening interaction when taken with {v} Dronedarone
Gilteritinib {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Gilteritinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Gilteritinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine
Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Gilteritinib may lead to a major life threatening interaction when taken with Dronedarone
Gilteritinib may lead to a major life threatening interaction when taken with Troleandomycin